CTD²: Cancer Target Discovery and Development

CTD2 bridges the gap between the enormous volumes of data generated by genomic characterization studies and the ability to use these data for the development of human cancer therapeutics. It specializes in computational and functional genomics approaches critical for translating next-generation sequencing data, as well as high-throughput and high content small molecule and genetic screens.

Banner for CTD squared program. Links to CTD squared program page
Last updated: January 12, 2018

News & Publications

previousnext
CTD²
June 28, 2018

Chimeric antigen receptors (CARs) significantly enhance the anti-tumor activity of immune effector cells. Although most studies have evaluated CAR expression in T cells, here we evaluate different CAR constructs that improve natural killer (NK) cell-mediated killing. We identified a CAR...

Image of 	Breast Cancer Stage IIIB
CTD²
June 25, 2018

Dysregulation of the PI3K-AKT-mTOR signaling network is a prominent feature of breast cancers. However, clinical responses to drugs targeting this pathway have been modest, possibly because of dynamic changes in cellular signaling that drive resistance and limit drug efficacy. Using a...

Image of the pancreas and nearby organs and structures in the digestive tract.
CTD²
June 18, 2018

We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted activity of master regulator proteins that...

CTD²
June 09, 2018

Increased androgen receptor (AR) activity drives therapeutic resistance in advanced prostate cancer. The most common resistance mechanism is amplification of this locus presumably targeting the AR gene. Here, we identify and characterize a somatically acquired AR enhancer located 650 kb...

Image of TFAP4, a synthetic lethal candidate and master regulator of MYCN-amplified neuroblastoma
CTD²
,
TARGET
June 07, 2018

Despite the identification of MYCN amplification as an adverse prognostic marker in neuroblastoma, MYCN inhibitors have yet to be developed. Here, by integrating evidence from a whole-genome shRNA library screen and the computational inference of master regulator proteins, we identify...

O
O
O
O
O